

Datasheet for 600-401-C29S**BrdU Antibody****Overview**

Description:	Anti-BrdU (RABBIT) Antibody - 600-401-C29S
Item No.:	600-401-C29S
Size:	25 µL
Applications:	Dot Blot, ELISA, IHC, FC, IF, IP, Multiplex, Other
Reactivity:	BrdU
Host Species:	Rabbit

Product Details

Background:	Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic thymidine nucleoside analog. BrdU is commonly used to allow the detection of growing or proliferating cells in living tissues. During the S-phase of cell division, DNA replication occurs, and BrdU can be incorporated into the newly synthesized DNA by substituting for naturally occurring thymidine. Antibodies specific for BrdU are subsequently used to detect the incorporated BrdU thymidine analog. This highlights cells that were actively replicating their DNA and is suggestive of actively growing cells. Antibody binding usually requires the DNA to be denatured, typically by exposing the cells to acid or heat.
Synonyms:	rabbit anti-BrdU antibody, bromodeoxyuridine, 5-bromo-2'-deoxyuridine
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Reactivity:	BrdU
Immunogen Type:	Other
Immunogen:	Anti-BrdU affinity purified antibody was purified from monospecific rabbit antiserum prepared via repeated immunizations with BromodeoxyUridine-KLH.
Purity/Specificity:	BrdU Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography.

Application Details

Tested Applications:	Dot Blot, ELISA, IHC
Suggested Applications:	FC, IF, IP, Multiplex, Other (Based on references)
Application Note:	Anti-BrdU Antibody has been tested by ELISA, slot blot, IHC, and is suitable for immunofluorescence microscopy and flow cytometry. Specific conditions for reactivity should be optimized by the end user. Expect to detect incorporated BrdU thymidine analog from replicated cells.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:2000 - 1:10,000
FC:	1:50-1:100
IF:	1:500
IHC:	1:100-1:500
IP:	User Optimized
WB:	User Optimized

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1.1 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None


Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store BrdU Antibody at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 µL). To minimize loss of volume dilute 1:10 by adding 225 µL of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.

Expiration:

Expiration date is three (3) months from date of receipt.

Images





Immunohistochemistry

SOX2 represses proliferation in the developing spinal cord and stomach. (A) Percentage of cells expressing high or low levels of SOX2 labelled by a one hour pulse of BrdU in the E11.5 mouse spinal cord. Dotted lines in insets surround area of greatest BrdU incorporation. (B) Average background normalized SOX2 expression level and percentage of cells labelled by a one hour pulse of BrdU in the E11.5, E13.5 and E15.5 anterior and posterior stomach. (C) Percentage of electroporated cells in the chick spinal cord labelled by a 30 minute pulse of BrdU following misexpression of GFP, SOX2 or dnSOXB1. (D) Percentage of electroporated cells in E13.5 stomach explants labelled by a 30 minute pulse of BrdU following overexpression of GFP, SOX2 or dnSOXB1. All error bars represent standard deviations between experiments and p-values are calculated with two sided, unpaired t-tests (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$). Figure provided by CiteAb. Source: PLoS Genet, PMID: 29432416.

Immunofluorescence Microscopy


(L) Early S-phase HeLa cells, untreated or HS treated (45.5°C, 30 min) and allowed to recover for 0 or 3 h, were then pulsed with 5-fluorouracil (5-FU; 5 mM) for 3 h. 5-FU was revealed by immunocytochemistry (green) with rabbit polyclonal anti-BrdU antibodies (p/n 600-401-C29) and Alexa Fluor 488-conjugated goat anti-rabbit antibody. The DNA was stained with DAPI (blue). Scale bar: 25 μ m. Fig 3. PMID: 26032771






Immunofluorescence Microscopy

(A and B) HMVEC-d cells pre-incubated with or without 1 μ M C-646 for 2 h were washed, infected with BrdU genome labeled KSHV (30 DNA copies/cell) for 2 h, washed and incubated with or without 1 μ M C-646 for 4 h. Cells were processed, incubated with anti-BrdU antibodies, washed, and reacted with Alexa Fluor-488 (green) secondary antibodies to detect BrdU-KSHV. These slides were subjected to PLA (A) with mouse anti-IFI16 and rabbit-IFI16 antibodies or (B) with anti-IFI16 and anti-acetylated lysine antibodies. Boxed areas are enlarged. The yellow arrows in (A) and (B) indicate the cytoplasmic IFI16 or acetylated IFI16, respectively. The white arrows in (A) indicate colocalization of IFI16 PLA spots with BrdU labeled KSHV genome. The white arrows in (B) indicate colocalization of acetylated IFI16 PLA spots with BrdU labeled KSHV genome. Fig 9. PMID: 26134128




Flow Cytometry

(B) Cell cycle analysis. NS1-S1 and NS1mTAD2-S1 cells were treated with Dox (Dox+; 5 μ g/ml) or not (Dox-) for 72 h and then incubated with BrdU, followed by treatment with 1N HCl. Treated cells were stained with an anti-BrdU antibody, and secondary antibody, and DAPI prior to flow cytometry. The numbers in each histogram are percentages of the cell populations with all BrdU-positive (S-phase), and BrdU-negative cell populations of 2N and 4N DNA content (G1- and G2-phase, respectively). Fig 1. PMID: 28264028



Flow Cytometry

(A) Cell cycle analysis. NS1-S1 cells were treated with the ATR-specific inhibitor VE821 at 3 h prior to Dox treatment. At 72 h post-treatment, the cells were then collected and co-stained with an anti-BrdU antibody and DAPI prior for flow cytometry. DMSO-treated NS1-S1 cells were used as a control. Fig 7. PMID: 28264028





Immunofluorescence Microscopy

M-STED of transcription foci within intact MCF10A nuclei. a Example of acquired stack images, from the confocal (F1) to maximum STED power (F8) (Pmax = 43.3 mW). BrU was immunostained with anti-BrdU(rabbit)/anti-rabbit Chromeo488. Color scale: normalized intensity. Scale bar: 3 μm. Fig 3. PMID: 30143630.


Diagram

Bromodeoxyuridine (BrdU) chemical structure representation.



Immunofluorescence Microscopy

Immunofluorescence microscopy images of paraformaldehyde-fixed, paraffin-embedded pancreas sections stained with antibodies against BrdU (red or pink) and counterstained with DAPI (blue) and imaged with a 40× objective. DAPI stained nuclei (blue) indicate non-dividing cells, immunostained red and pink nuclei indicate actively dividing pancreatic β-cells. The antibodies were diluted to 2.7 μg/ml. and incubated with tissue sections overnight at 4 degrees. Donkey anti-rabbit secondary antibody was diluted 1:2500.



Immunofluorescence Microscopy

Immunofluorescence Microscopy of Rabbit anti-BrdU antibody. Tissue: 293T cells transfected expressing GFP-MCM9 L. Fixation: 0.5% PFA. Antigen retrieval: not required. Primary antibody: BrdU antibody at 10 µg/mL for 1 h at RT. Secondary antibody: Anti-rabbit ATTO550 secondary antibody at 1:10,000 for 45 min at RT. Localization: BrdU is nuclear. Staining: BrdU in merged image shows with green and purple fluorescent signal with DAPI nuclear counterstain.

References

- Watkins RD et al. The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma. *Cells*. (2025)
- Pradhan SK et al. Developmental Changes in Genome Replication Progression in Pluripotent versus Differentiated Human Cells. *Genes (Basel)*. (2024)
- Ning K et al. Identification of AXL as a co-receptor for human parvovirus B19 infection of human erythroid progenitors. *Sci Adv*. (2023)
- Sasaki L et al. Intracrine activity involving NAD-dependent circadian steroidogenic activity governs age-associated meibomian gland dysfunction. *Nat Aging*. (2022)
- Iskusnykh, IY et al. Intrauterine growth restriction compromises cerebellar development by affecting radial migration of granule cells via the JamC/Pard3a molecular pathway. *Experimental Neurology* (2021)
- Li D et al. IFI16 Isoforms with Cytoplasmic and Nuclear Locations Play Differential Roles in Recognizing Invaded DNA Viruses. *J Immunol*. (2021)
- Kint S et al. Single cell epigenetic visualization assay. *Nucleic Acids Res*. (2021)
- Kim HK et al. Notch Signaling Controls Oligodendrocyte Regeneration in the Injured Telencephalon of Adult Zebrafish. *Exp Neurobiol*. (2020)
- Liu B et al. An inducible circular RNA circKcnt2 inhibits ILC3 activation to facilitate colitis resolution. *Nat Commun*. (2020)
- Horiguchi, K et al. Expression and functions of cluster of differentiation 9 and 81 in rat mammary epithelial cells. *The Journal of Reproduction and Development* (2020)
- Sheng C et al. PCNA-mediated degradation of p21 coordinates the DNA damage response and cell cycle regulation in individual cells. *Cell Rep*. (2019)
- Velichko AK et al. Hypoosmotic stress induces R loop formation in nucleoli and ATR/ATM-dependent silencing of nucleolar transcription. *Nucleic Acids Res*. (2019)

- Roy A et al. IFI16, a nuclear innate immune DNA sensor, mediates epigenetic silencing of herpesvirus genomes by its association with H3K9 methyltransferases SUV39H1 and GLP. *Elife* (2019)
- Chizhikov VV et al. Early dorsomedial tissue interactions regulate gyrification of distal neocortex. *Nat Commun.* (2019)
- Hagey et al. SOX2 regulates common and specific stem cell features in the CNS and endoderm derived organs. *PLOS Genetics* (2018)
- Sarmiento et al. Exploiting the tunability of stimulated emission depletion microscopy for super-resolution imaging of nuclear structures. *Nature Communications* (2018)
- Ganaie et al. RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication. *Journal of Virology* (2018)
- Parisotto et al. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo. *Journal of Experimental Medicine* (2018)
- Xu et al. Parvovirus B19 NS1 protein induces cell cycle arrest at G2-phase by activating the ATR-CDC25C-CDK1 pathway. *PLOS Pathogens* (2017)
- Xu et al. WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. *Nature Communications* (2017)
- Narayan RS et al. Identification of MEK162 as a radiosensitizer for the treatment of glioblastoma. *Mol Cancer Ther.* (2017)
- Luzhin AV et al. Automated Analysis of Cell Cycle Phase-Specific DNA Damage Reveals Phase-Specific Differences in Cell Sensitivity to Etoposide. *J Cell Biochem.* (2016)
- Shen et al. Analysis of cis and trans Requirements for DNA Replication at the Right-End Hairpin of the Human Bocavirus 1 Genome. *Journal of Virology* (2016)
- Shin et al. Vegfa signals through ERK to promote angiogenesis, but not artery differentiation. *Development* (2016)
- Velichko et al. Mechanism of heat stress-induced cellular senescence elucidates the exclusive vulnerability of early S-phase cells to mild genotoxic stress. *Nucleic Acids Research* (2015)
- Zhang, J et al. The transcriptional coactivator Taz regulates proximodistal patterning of the pronephric tubule in zebrafish. *Mechanisms of Development* (2015)
- Ansari, MA et al. Herpesvirus Genome Recognition Induced Acetylation of Nuclear IFI16 Is Essential for Its Cytoplasmic Translocation, Inflammasome and IFN- β Responses. *PloS Pathogens* (2015)
- Tulina NM et al. Day–night cycles and the sleep-promoting factor, Sleepless, affect stem cell activity in the *Drosophila* testis. *Proc Natl Acad Sci USA* (2014)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.